安罗替尼二线治疗晚期非小细胞肺癌的临床效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect and toxicity of Amlotinib in second-line treatment of advanced non-small cell lung cancer. Methods A total of 52 patients with advanced non-small cell lung cancer admitted to People′s Hospital of Chaozhou City from January 2019 to March 2020 were selected as the research objects. After progression of first-line chemotherapy, the patients were divided into chemotherapy group (32 cases) and Amlotinib group(20 cases) on a voluntary basis. Patients in the chemotherapy group were treated with Paclitaxel combined with Cisplatin, and patients in the Amlotinib group were treated with Amlotinib Capsules orally. The short-term efficacy and the occurrence of toxic and side effects were compared between the two groups. Results There were no statistically significant differences in objective effective rate and disease control rate between the two groups (P＞0.05). The incidence of anorexia and gastrointestinal reactions in the Amlotinib group were lower than those in the chemotherapy group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the incidence rates of bleeding, hypertension, myelosuppression, hand-foot syndrome, oral ulcer, liver and kidney function injury and fatigue between the two groups (P＞0.05). Conclusion The clinical effect of Amlotinib as a second-line regimen in advanced non-small cell patients is similar to that of chemotherapy , and the adverse reactions are fewer.

Key words： Amlotinib Non-small cell lung cancer Chemotherapy Effective rate Adverse reactions

Received: 30 November 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I12/108

[1]	Sun Y，Niu W，Du F，et al.Safety，pharmacokinetics，and antitumor properties of anlotinib，an oral multi-target tyrosine kinase inhibitor，in patients with advanced refractory solid tumors[J].J Hematol Oncol，2016，9（1）：105.
[2]	罗详冲，刘晶晶，李高峰.安罗替尼治疗晚期恶性肿瘤的研究进展[J].肿瘤，2019，39（12）：1025-1030.
[3]	Eisenhauer EA，Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J].Eur J Cancer，2009，45（2）：228-247.
[4]	Chen AP，Setser A，Anadkat MJ，et al.Grading dermatologic adverse events of cancer treatments：the Common Terminology Criteria for Adverse Events Version 4.0[J].J Am Acad Dermatol，2012，67（5）：1025-1039.
[5]	Jayson GC，Kerbel R，Ellis LM，et al.Antiangiogenic therapy in oncology：current status and future directions[J].Lancet，2016，388（10043）：518-529.
[6]	刘平莉，陈碧，罗涛，等.贝伐珠单抗辅助常规化疗治疗非小细胞肺癌临床效果与安全性[J].临床和实验医学杂志，2020，19（21）：2291-2295.
[7]	赵仔君，谷晓媛，张为强，等.贝伐珠单抗联合阿法替尼治疗非小细胞肺癌临床疗效观察[J].海南医学院学报，2019，25（2）：129-132.
[8]	净卫娟，陈维英，陈鸿里.白细胞介素-4 与血管内皮抑素在Lewis 肺癌小鼠中的抗肿瘤效应及相关机制研究[J].临床和实验医学杂志，2020，19（20）：2132-3136.
[9]	Xie C，Wan X，Quan H，et al.Preclinical characterization of anlotinib，a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J].Cancer Sci，2018，109（4）：1207-1219.
[10]	宋永安，张雪燕，徐志伟，等.安罗替尼对肺癌A549 细胞增殖、迁移侵袭的影响[J].成都医学院学报，2019，24（3）：255-259.
[11]	肖锋，肖茂良，李孝君.安罗替尼对晚期NSCLC 患者免疫功能的影响[J].湖南师范大学学报（医学版），2020，17（4）：64-67.
[14]	高亭，何小鹏，李敏，等.安罗替尼一线治疗晚期非小细胞肺癌的临床疗效观察[J].浙江医学，2019，41（23），2543-2545.
[15]	陈轩，李真斌.安罗替尼治疗晚期非小细胞肺癌的临床疗效与安全性[J].当代医学，2020，26（22）：137-139.
[16]	赵文文，肖超，冯青青，等.安罗替尼三线治疗广泛期小细胞肺癌的效果[J].青岛大学学报（医学版），2020，56（6）：727-729.
[12]	Liu Z，Wang J，Meng Z，et al.P3.01-084 Analysis on ALTER0303 Trial：aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC[J].J Thorac Oncol，2017，12（11）：S2234-S2235.
[13]	Han B，Li K，Wang Q，et al.Effect of Anlotinib as a third-Line or further treatment on overall survival of patients with advanced non-small cell lung cancer：The ALTER0303 phase 3 randomized clinical trial[J].JAMA Oncol，2018，4（11）：1569-1575.
[17]	金振兴，杜秀平.盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察[J].临床与病理杂志，2020，40（4）：905-912.
[18]	李莲港，姜军.安罗替尼在肺癌治疗中的研究进展[J].中国当代医药，2020，27（2）：12-14.